Posted by Michael Wonder on 22 Jul 2022
Daewoong Pharmaceutical gets first Korean US FDA fast track for new idiopathic pulmonary fibrosis drug
20 July 2022 - First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach $6.1 billion globally by 2030
As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical's new medication DWN12088 has been fast-tracked by the US FDA, the first time a Korean pharma company has been awarded this status.
